The Gillett Health Podcast Are Glp1's getting banned
Mar 18, 2026
A lively discussion about potential bans on compounded GLP-1 drugs and recent FDA moves. They unpack which manufacturers and imports are being green-listed and how enforcement might target telemedicine and sketchy suppliers. The conversation weighs patient access against regulatory risk, examines trends in who stays on GLP-1s, and gives practical steps for safe treatment and advocacy.
AI Snips
Chapters
Transcript
Episode notes
FDA Focuses On Source Quality Not Blanket Ban
- The FDA is targeting poor-quality suppliers and telemedicine companies selling direct-to-consumer compounded GLP-1s.
- Kyle Gillett MD and James O'Hara explain the agency wants to restrict API access and enforce good manufacturing practices rather than ban legitimate compounding pharmacies.
FDA Green Lists Some API Producers
- The FDA listed approved API producers as a way to allow legitimate imports while cutting off sketchy suppliers and telemedicine platforms.
- Kyle notes some facilities producing even nonapproved molecules like tirzepatide were green-lit, showing nuance in enforcement.
Avoid Sketchy Peptide Vendors For GLP-1s
- Avoid non-pharmacy peptide vendors and sketchy telemedicine clinics for GLP-1s because quality and manufacturing practices vary widely.
- The hosts urge using reputable pharmacies or clinics that can demonstrate good manufacturing and API sourcing.